A Pharmaceutical Study on Controlled Release Doxazosin mesylate in Solid Dosage Forms

Abstract

Controlled-release dosage forms offer several advantages over conventional therapy. These advantages include, maintenance of drug level within the desired range, thus achieving better plasma profile, fewer drug administration, lower toxicity, optimal use of drug in question and increased patient compliance. Many physical and chemical approaches have been applied to produce well-characterized dosage forms that control drug input into the body within the specifications of the desired release profile. This is generally accomplished by attempting to obtain "zero-order" release from the dosage form, i.e., the rate of drug release is independent of the drug concentration.

Doxazosin mesylate; Doxazosin methanesulphonate IS an alpha1 - adrenoceptor blocker. It is used in the management of hypertension and in benign prostatic hyperplasia (BPH) to relieve urinary obstruction.

In a trial to control the release of doxazosin mesylate over an extended period of time, controlled-release doxazosin mesylate tablets that fulfill the requirements for extended release medications were prepared and evaluated in view of their release rate profile, physical and chemical stability. Also, the formulated tablets overcome the stability problems of commercially available tablets (Cardura XL®) that controlled release of the drug using osmotic pump